{"filing":{"accession_number":"0001213900-26-073978","cik":"0001536196","ticker":"CANF","company_name":"Can-Fite BioPharma Ltd.","form":"6-K","filing_date":"2026-07-01","report_date":null,"primary_document":"ea0296672-6k_canfite.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1536196/000121390026073978/ea0296672-6k_canfite.htm"},"events":[{"id":15257,"run_id":13614,"accession_number":"0001213900-26-073978","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.25,"summary":"This is a clinical trial results announcement for Namodenoson in a Phase 2a pancreatic cancer study. While it discloses positive safety and survival outcomes, it is not a financial earnings release (no quarterly or annual financial results). The disclosure is material to investors as it reports clinical progress on a key pipeline asset, but the event_type taxonomy does not contain a specific category for clinical trial results or product development milestones. This is an operational/strategic disclosure about drug development progress that does not fit neatly into the provided categories.","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-07-01","form":"6-K","submitted_at":null,"items":[{"id":12946,"accession_number":"0001213900-26-073978","item_number":"EX-99.1","item_title":"ea029667201ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.25,"reasoning":"This is a clinical trial results announcement for Namodenoson in a Phase 2a pancreatic cancer study. While it discloses positive safety and survival outcomes, it is not a financial earnings release (no quarterly or annual financial results). The disclosure is material to investors as it reports clinical progress on a key pipeline asset, but the event_type taxonomy does not contain a specific category for clinical trial results or product development milestones. This is an operational/strategic disclosure about drug development progress that does not fit neatly into the provided categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:33:45.264151+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12946,"accession_number":"0001213900-26-073978","item_number":"EX-99.1","item_title":"ea029667201ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.25,"reasoning":"This is a clinical trial results announcement for Namodenoson in a Phase 2a pancreatic cancer study. While it discloses positive safety and survival outcomes, it is not a financial earnings release (no quarterly or annual financial results). The disclosure is material to investors as it reports clinical progress on a key pipeline asset, but the event_type taxonomy does not contain a specific category for clinical trial results or product development milestones. This is an operational/strategic disclosure about drug development progress that does not fit neatly into the provided categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:33:45.264151+00:00","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-07-01"}]}